drugset
drugset / Trial / NCT03535246

Immunotherapy Based on Tumor Associated Antigen-specific Immune Effector Cells

NCT03535246 ↗

Phase 1/2 Recruiting 100 enrolled Shenzhen Geno-Immune Medical Institute
NaSingle-groupOpen-labelTreatment

Summary

The primary objectives are to evaluate the safety and efficacy of infusion of autologous tumor associated antigen-specific engineered immune effector cells (EIE).

Timeline

Start
2025-07-01
Primary completion
2028-06-30
Completion
2029-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Engineered immune effector cells (EIE) Cell therapy — Intravenous

Indications

cancer